GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » Long-Term Capital Lease Obligation

China National Accord Medicines (SZSE:000028) Long-Term Capital Lease Obligation : ¥1,642 Mil (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines Long-Term Capital Lease Obligation?

China National Accord Medicines's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,642 Mil.

China National Accord Medicines's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (¥1,371 Mil) to Dec. 2023 (¥1,452 Mil) and increased from Dec. 2023 (¥1,452 Mil) to Mar. 2024 (¥1,642 Mil).

China National Accord Medicines's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (¥1,375 Mil) to Dec. 2022 (¥1,327 Mil) but then increased from Dec. 2022 (¥1,327 Mil) to Dec. 2023 (¥1,452 Mil).


China National Accord Medicines Long-Term Capital Lease Obligation Historical Data

The historical data trend for China National Accord Medicines's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Long-Term Capital Lease Obligation Chart

China National Accord Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,208.45 1,303.05 1,375.43 1,327.40 1,451.79

China National Accord Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,311.79 1,350.00 1,371.11 1,451.79 1,642.18

China National Accord Medicines  (SZSE:000028) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

China National Accord Medicines Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
Executives
Su Wei Wei Independent director
Chen Chang Bing Secretary Dong
Peng Juan Director
Fu Ming Zhong Director

China National Accord Medicines (SZSE:000028) Headlines

No Headlines